This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Dry age-related macular degeneration (includes geographic atrophy), under 50 years
DRY_AMD_EARLY
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersPre-conditions: EVENT_AGE<50 Registry filters:
2 out of 7 registries used, show all original rules. |
164 |
4. Check minimum number of eventsNone |
164 |
5. Include endpointsNone |
164 |
6. Filter based on genotype QC (FinnGen only) |
158 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF12
- Parent code in ICD-10
- H35
- Name in latin
- Degeneratio maculae senilis atrophica
Similar endpoints
↥List of similar endpoints to
Dry age-related macular degeneration (includes geographic atrophy), under 50 years
based on the number of shared cases.
Similar with more cases:
- Degeneration of macula and posterior pole
- Other retinal disorders
- Disorders of choroid and retina
- Diseases of the eye and adnexa
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 158 | 90 | 68 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 46.01 | 46.15 | 45.84 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 164
- Matched controls
- 1640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H35.30
ICD-10 Finland
Kuhnt-Junius degeneration
3716.1
204.1
157
9
H35.39
ICD-10 Finland
Degeneration of macula and posterior pole
56.1
33.6
39
9
XCW99
NOMESCO Finland
Other investigative procedure of eye
8.4
31.2
49
79
XCK10
NOMESCO Finland
Photography of fundus of eye
8.9
31.1
46
69
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
+∞
20.2
19
*
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
8.0
17.1
25
36
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.4
16.7
56
174
H35.7
ICD-10 Finland
Separation of retinal layers
28.0
16.5
22
9
H35.31
ICD-10 Finland
Senile macular degeneration (atrophic)(exudative)
33.4
14.2
18
6
XCK00
NOMESCO Finland
Perimetry
6.7
14.0
24
41
H35.9
ICD-10 Finland
Retinal disorder, unspecified
75.9
12.8
14
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
11.9
11.7
21
20
XCD20
NOMESCO Finland
Photoangiography of eye
22.0
11.4
16
8
ZXA10
NOMESCO Finland
Bilateral
3.6
10.9
43
146
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.4
10.8
30
79
S01EC01
ATC
acetazolamide; systemic
20.4
10.5
15
8
CJB10
NOMESCO Finland
Laser discission of secondary cataract
9.2
9.4
19
23
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
3.3
9.1
41
150
Z96.1
ICD-10 Finland
Presence of intraocular lens
4.1
8.7
26
72
3625A
ICD-9 Finland
Other retinal disorders, Degeneration of macula and posterior pole[DEGENERATIO MACULAE NONEXSUDATIVA]
+∞
8.4
8
*
CKC10
NOMESCO Finland
Local photocoagulation of retina
14.3
7.5
12
9
H35.0
ICD-10 Finland
Background retinopathy and retinal vascular changes
83.7
7.5
8
*
Z3229
NOMESCO Finland
Other healthcare associate professional
4.0
7.0
21
58
H26.4
ICD-10 Finland
After-cataract
5.5
6.4
18
36
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.0
6.1
30
114
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Ophthalmology
18 [38004463]
18 [38004463]
1.6e+00
2.6e+00
3.4e+00
1.0e+50
3.3e+00
3.4e+00
2.5e+00
cases:22.56%
controls:5.46%
cases:24.39%
controls:2.45%
cases:12.80%
controls:0.49%
cases:95.12%
controls:0.00%
cases:15.85%
controls:0.67%
cases:47.24%
controls:2.84%
cases:51.61%
controls:7.73%
37
89
127
1542
40
40
124
1591
21
8
143
1623
156
0
8
1631
26
11
138
1620
77
46
86
1572
80
119
75
1420
Outpatient Visit
OP [9202]
OP [9202]
6.5e-01
9.5e-01
1.6e+00
6.7e+00
1.4e+00
1.3e+00
1.3e+00
cases:65.85%
controls:50.21%
cases:51.22%
controls:28.82%
cases:25.00%
controls:6.38%
cases:78.05%
controls:0.43%
cases:23.78%
controls:7.48%
cases:61.96%
controls:29.91%
cases:84.52%
controls:60.43%
108
819
56
812
84
470
80
1161
41
104
123
1527
128
7
36
1624
39
122
125
1509
101
484
62
1134
131
930
24
609
Photography of fundus of eye
XCK10 [2001301381]
XCK10 [2001301381]
2.1e+00
—
—
1.0e+50
—
2.5e+00
3.1e+00
cases:4.88%
controls:0.61%
—
—
—
—
cases:7.93%
controls:0.00%
—
—
cases:4.91%
controls:0.43%
cases:12.26%
controls:0.65%
8
10
156
1621
—
—
13
0
151
1631
—
8
7
155
1611
19
10
136
1529
Emergency Room Visit
ER [9203]
ER [9203]
5.5e-01
7.7e-01
2.2e+00
1.0e+50
1.9e+00
9.0e-01
6.0e-01
cases:32.32%
controls:21.64%
cases:14.63%
controls:7.36%
cases:6.10%
controls:0.74%
cases:4.27%
controls:0.00%
cases:4.88%
controls:0.80%
cases:17.79%
controls:8.10%
cases:38.71%
controls:25.73%
53
353
111
1278
24
120
140
1511
10
12
154
1619
7
0
157
1631
8
13
156
1618
29
131
134
1487
60
396
95
1143
Internal Medicine
11 [38004456]
11 [38004456]
4.5e-01
9.6e-01
1.9e+00
—
1.6e+00
1.2e+00
7.7e-01
cases:21.34%
controls:14.78%
cases:12.80%
controls:5.33%
cases:5.49%
controls:0.86%
—
—
cases:4.27%
controls:0.92%
cases:16.56%
controls:5.87%
cases:27.74%
controls:15.14%
35
241
129
1390
21
87
143
1544
9
14
155
1617
—
7
15
157
1616
27
95
136
1523
43
233
112
1306
simvastatin; oral
C10AA01 [21601856]
C10AA01 [21601856]
1.1e+00
1.2e+00
—
—
—
1.2e+00
8.6e-01
cases:7.93%
controls:2.76%
cases:7.93%
controls:2.51%
—
—
—
—
—
—
cases:9.20%
controls:2.84%
cases:15.48%
controls:7.21%
13
45
151
1586
13
41
151
1590
—
—
—
15
46
148
1572
24
111
131
1428
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
6.3e-01
1.2e+00
2.2e+00
—
—
7.6e-01
6.9e-01
cases:14.02%
controls:7.97%
cases:9.15%
controls:3.07%
cases:3.66%
controls:0.43%
—
—
—
—
cases:7.36%
controls:3.58%
cases:23.23%
controls:13.13%
23
130
141
1501
15
50
149
1581
6
7
158
1624
—
—
12
58
151
1560
36
202
119
1337
Neurology
13 [38004458]
13 [38004458]
6.2e-01
1.3e+00
2.1e+00
—
1.6e+00
1.5e+00
9.6e-01
cases:10.98%
controls:6.19%
cases:7.93%
controls:2.33%
cases:3.05%
controls:0.37%
—
—
cases:3.05%
controls:0.61%
cases:9.82%
controls:2.35%
cases:17.42%
controls:7.47%
18
101
146
1530
13
38
151
1593
5
6
159
1625
—
5
10
159
1621
16
38
147
1580
27
115
128
1424
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
1.0e+00
—
—
—
—
1.9e+00
1.3e+00
cases:3.05%
controls:1.10%
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.68%
cases:7.74%
controls:2.27%
5
18
159
1613
—
—
—
—
7
11
156
1607
12
35
143
1504
Inpatient Hospital
21 [8717]
21 [8717]
3.6e-01
7.6e-01
2.3e+00
—
—
4.9e-01
7.6e-01
cases:32.32%
controls:25.08%
cases:13.41%
controls:6.74%
cases:5.49%
controls:0.55%
—
—
—
—
cases:12.27%
controls:7.91%
cases:36.13%
controls:20.92%
53
409
111
1222
22
110
142
1521
9
9
155
1622
—
—
20
128
143
1490
56
322
99
1217
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
CK2X4 [2001301456]
—
—
—
1.0e+50
—
—
3.0e+00
—
—
—
—
—
—
cases:3.05%
controls:0.00%
—
—
—
—
cases:6.45%
controls:0.32%
—
—
—
5
0
159
1631
—
—
10
5
145
1534
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
6.5e-01
8.7e-01
2.0e+00
—
—
9.3e-01
9.3e-01
cases:7.93%
controls:4.29%
cases:7.32%
controls:3.19%
cases:3.66%
controls:0.49%
—
—
—
—
cases:9.20%
controls:3.83%
cases:14.19%
controls:6.11%
13
70
151
1561
12
52
152
1579
6
8
158
1623
—
—
15
62
148
1556
22
94
133
1445
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
3.6e-01
4.3e-01
6.6e-01
2.8e+00
3.9e-01
3.0e-01
2.7e-01
cases:37.80%
controls:29.80%
cases:32.93%
controls:24.22%
cases:13.41%
controls:7.42%
cases:10.37%
controls:0.67%
cases:12.20%
controls:8.58%
cases:32.52%
controls:26.33%
cases:55.48%
controls:48.86%
62
486
102
1145
54
395
110
1236
22
121
142
1510
17
11
147
1620
20
140
144
1491
53
426
110
1192
86
752
69
787
latanoprost
S01EE01 [21603710]
S01EE01 [21603710]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.52%
controls:0.32%
—
—
—
—
—
—
7
5
148
1534
Perimetry
XCK00 [2001301380]
XCK00 [2001301380]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.32%
—
—
—
—
—
—
6
5
149
1534
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
3.5e-01
5.6e-01
6.4e-01
1.8e+00
5.5e-01
6.0e-01
2.7e-01
cases:90.24%
controls:86.76%
cases:79.88%
controls:69.41%
cases:42.07%
controls:27.77%
cases:6.10%
controls:1.04%
cases:40.24%
controls:28.02%
cases:82.82%
controls:72.56%
cases:93.55%
controls:91.68%
148
1415
16
216
131
1132
33
499
69
453
95
1178
10
17
154
1614
66
457
98
1174
135
1174
28
444
145
1411
10
128
Glaucoma suspect
H40.0 [45567051]
H40.0 [45567051]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.39%
—
—
—
—
—
—
6
6
149
1533
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:0.71%
—
—
—
—
—
—
9
11
146
1528
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
Z00.4 [45605094]
-1.0e+50
—
—
—
—
—
2.1e+00
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:4.52%
controls:0.58%
0
7
164
1624
—
—
—
—
—
7
9
148
1530
Infectious Disease
44 [38004484]
44 [38004484]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:0.78%
—
—
—
—
—
—
9
12
146
1527
Pain general/multiple sites
A01 [2002000142]
A01 [2002000142]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.52%
—
—
—
—
—
—
6
8
149
1531
Treatment-related counselling outside office
SPAT1249 [2001700350]
SPAT1249 [2001700350]
5.5e-01
2.0e+00
—
—
—
1.1e+00
7.0e-01
cases:4.88%
controls:2.88%
cases:3.66%
controls:0.49%
—
—
—
—
—
—
cases:4.29%
controls:1.42%
cases:9.68%
controls:5.07%
8
47
156
1584
6
8
158
1623
—
—
—
7
23
156
1595
15
78
140
1461
Psychiatry
26 [38004469]
26 [38004469]
9.5e-01
1.2e+00
1.6e+00
—
—
6.4e-01
1.1e+00
cases:10.98%
controls:4.54%
cases:6.71%
controls:2.21%
cases:3.66%
controls:0.74%
—
—
—
—
cases:4.91%
controls:2.66%
cases:13.55%
controls:5.20%
18
74
146
1557
11
36
153
1595
6
12
158
1619
—
—
8
43
155
1575
21
80
134
1459
Other investigative procedure of eye
XCW99 [2001301491]
XCW99 [2001301491]
—
2.1e+00
—
1.0e+50
—
—
2.0e+00
—
—
cases:3.05%
controls:0.37%
—
—
cases:11.59%
controls:0.00%
—
—
—
—
cases:8.39%
controls:1.23%
—
5
6
159
1625
—
19
0
145
1631
—
—
13
19
142
1520
Bilateral
ZXA10 [2001311348]
ZXA10 [2001311348]
—
—
—
1.0e+50
—
—
2.0e+00
—
—
—
—
—
—
cases:3.66%
controls:0.00%
—
—
—
—
cases:7.10%
controls:1.04%
—
—
—
6
0
158
1631
—
—
11
16
144
1523
quetiapine; oral
N05AH04 [21604544]
N05AH04 [21604544]
1.0e+00
1.9e+00
—
—
—
1.3e+00
1.1e+00
cases:4.27%
controls:1.59%
cases:6.10%
controls:0.92%
—
—
—
—
—
—
cases:3.68%
controls:1.05%
cases:7.74%
controls:2.73%
7
26
157
1605
10
15
154
1616
—
—
—
6
17
157
1601
12
42
143
1497
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
9.7e-01
5.7e-01
—
—
—
1.0e+00
9.5e-01
cases:14.02%
controls:5.82%
cases:4.27%
controls:2.45%
—
—
—
—
—
—
cases:5.52%
controls:2.10%
cases:15.48%
controls:6.63%
23
95
141
1536
7
40
157
1591
—
—
—
9
34
154
1584
24
102
131
1437
antibiotics in combination with other drugs
S01AA20 [21603571]
S01AA20 [21603571]
—
1.9e+00
—
—
—
1.5e+00
8.0e-01
—
—
cases:4.88%
controls:0.80%
—
—
—
—
—
—
cases:4.91%
controls:1.17%
cases:8.39%
controls:3.96%
—
8
13
156
1618
—
—
—
8
19
155
1599
13
61
142
1478
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
1.9e-01
1.7e-01
-1.0e+50
—
-1.0e+50
1.1e+00
7.4e-01
cases:9.76%
controls:8.22%
cases:4.27%
controls:3.62%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.55%
cases:9.82%
controls:3.46%
cases:25.16%
controls:13.84%
16
134
148
1497
7
59
157
1572
0
5
164
1626
—
0
9
164
1622
16
56
147
1562
39
213
116
1326
Laceration/cut
S18 [2002000983]
S18 [2002000983]
—
—
—
—
—
1.8e+00
9.2e-01
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.74%
cases:8.39%
controls:3.51%
—
—
—
—
—
7
12
156
1606
13
54
142
1485
No disease
A97 [2002000230]
A97 [2002000230]
1.2e+00
—
—
—
—
—
1.7e+00
cases:3.05%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:0.97%
5
15
159
1616
—
—
—
—
—
8
15
147
1524
Examination of eyes and vision
Z01.0 [45566391]
Z01.0 [45566391]
1.7e+00
—
—
—
—
—
8.5e-01
cases:6.10%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.69%
10
19
154
1612
—
—
—
—
—
6
26
149
1513
Headache
R51.80 [2000503603]
R51.80 [2000503603]
—
—
—
—
—
2.0e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.43%
cases:5.16%
controls:1.04%
—
—
—
—
—
5
7
158
1611
8
16
147
1523
Day surgery
ZXD20 [2001311388]
ZXD20 [2001311388]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:1.23%
—
—
—
—
—
—
9
19
146
1520
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:1.62%
—
—
—
—
—
—
11
25
144
1514
cromoglicic acid
S01GX01 [21605085]
S01GX01 [21605085]
1.5e+00
—
—
—
—
—
7.9e-01
cases:6.71%
controls:1.59%
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:2.73%
11
26
153
1605
—
—
—
—
—
9
42
146
1497
Rheumatology
66 [38004491]
66 [38004491]
9.7e-01
—
—
—
—
1.4e+00
1.4e+00
cases:4.88%
controls:1.90%
—
—
—
—
—
—
—
—
cases:4.29%
controls:1.11%
cases:6.45%
controls:1.69%
8
31
156
1600
—
—
—
—
7
18
156
1600
10
26
145
1513
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
5.2e-01
—
—
—
—
—
1.4e+00
cases:4.27%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
cases:10.97%
controls:2.99%
7
42
157
1589
—
—
—
—
—
17
46
138
1493
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
5.4e-01
1.3e+00
—
—
—
7.7e-01
3.9e-01
cases:7.93%
controls:4.78%
cases:7.32%
controls:2.08%
—
—
—
—
—
—
cases:4.29%
controls:2.04%
cases:12.90%
controls:9.10%
13
78
151
1553
12
34
152
1597
—
—
—
7
33
156
1585
20
140
135
1399
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
—
—
—
—
—
1.2e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.93%
cases:8.39%
controls:2.47%
—
—
—
—
—
5
15
158
1603
13
38
142
1501
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
1.2e+00
1.8e+00
—
—
—
8.3e-01
1.2e+00
cases:4.88%
controls:1.47%
cases:3.66%
controls:0.61%
—
—
—
—
—
—
cases:3.07%
controls:1.36%
cases:9.68%
controls:2.99%
8
24
156
1607
6
10
158
1621
—
—
—
5
22
158
1596
15
46
140
1493
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
3.2e-01
—
—
—
—
1.1e+00
1.2e+00
cases:5.49%
controls:4.05%
—
—
—
—
—
—
—
—
cases:3.07%
controls:1.05%
cases:9.68%
controls:2.99%
9
66
155
1565
—
—
—
—
5
17
158
1601
15
46
140
1493
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
9.4e-01
1.2e+00
—
—
—
9.0e-01
1.2e+00
cases:4.88%
controls:1.96%
cases:4.88%
controls:1.47%
—
—
—
—
—
—
cases:4.29%
controls:1.79%
cases:13.55%
controls:4.42%
8
32
156
1599
8
24
156
1607
—
—
—
7
29
156
1589
21
68
134
1471
Otolaryngology
4 [38004449]
4 [38004449]
1.2e-01
1.2e+00
—
—
—
1.1e+00
6.6e-01
cases:9.76%
controls:8.77%
cases:9.15%
controls:2.94%
—
—
—
—
—
—
cases:6.75%
controls:2.41%
cases:12.90%
controls:7.08%
16
143
148
1488
15
48
149
1583
—
—
—
11
39
152
1579
20
109
135
1430
Extraction of tooth
EBA00 [2001301923]
EBA00 [2001301923]
3.0e-01
—
—
—
—
1.4e+00
1.1e+00
cases:3.05%
controls:2.27%
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.80%
cases:10.32%
controls:3.57%
5
37
159
1594
—
—
—
—
5
13
158
1605
16
55
139
1484
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.39%
controls:2.92%
—
—
—
—
—
—
13
45
142
1494
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
8.5e-01
2.3e+00
—
—
—
—
1.1e+00
cases:6.10%
controls:2.70%
cases:3.05%
controls:0.31%
—
—
—
—
—
—
—
—
cases:9.03%
controls:3.31%
10
44
154
1587
5
5
159
1626
—
—
—
—
14
51
141
1488
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.0e+00
—
—
—
—
1.3e+00
1.1e+00
cases:8.54%
controls:3.31%
—
—
—
—
—
—
—
—
cases:4.29%
controls:1.17%
cases:9.03%
controls:3.31%
14
54
150
1577
—
—
—
—
7
19
156
1599
14
51
141
1488
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
4.8e-02
—
—
—
-1.0e+50
—
9.9e-01
cases:4.88%
controls:4.66%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:14.84%
controls:6.11%
8
76
156
1555
—
—
—
0
6
164
1625
—
23
94
132
1445
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
3.7e-01
1.1e+00
—
—
—
6.8e-01
9.5e-01
cases:6.10%
controls:4.29%
cases:4.88%
controls:1.72%
—
—
—
—
—
—
cases:4.29%
controls:2.22%
cases:16.13%
controls:6.95%
10
70
154
1561
8
28
156
1603
—
—
—
7
36
156
1582
25
107
130
1432
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
3.9e-01
9.3e-01
—
—
—
8.2e-01
2.5e-01
cases:11.59%
controls:8.15%
cases:11.59%
controls:4.90%
—
—
—
—
—
—
cases:11.04%
controls:5.19%
cases:19.35%
controls:15.79%
19
133
145
1498
19
80
145
1551
—
—
—
18
84
145
1534
30
243
125
1296
Outpatient Hospital
22 [8756]
22 [8756]
3.7e-01
7.6e-01
—
—
—
5.2e-01
9.1e-01
cases:23.78%
controls:17.72%
cases:10.37%
controls:5.15%
—
—
—
—
—
—
cases:8.59%
controls:5.32%
cases:32.26%
controls:16.11%
39
289
125
1342
17
84
147
1547
—
—
—
14
86
149
1532
50
248
105
1291
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
4.2e-01
4.7e-01
-1.0e+50
—
—
8.1e-01
4.4e-01
cases:32.93%
controls:24.46%
cases:11.59%
controls:7.54%
cases:0.00%
controls:0.98%
—
—
—
—
cases:17.18%
controls:8.47%
cases:34.84%
controls:25.54%
54
399
110
1232
19
123
145
1508
0
16
164
1615
—
—
28
137
135
1481
54
393
101
1146
Caries of dentine
K02.1 [45548134]
K02.1 [45548134]
3.4e-01
2.0e-01
-1.0e+50
—
-1.0e+50
4.2e-01
7.8e-01
cases:9.76%
controls:7.11%
cases:3.66%
controls:3.00%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.55%
cases:4.91%
controls:3.28%
cases:21.29%
controls:11.05%
16
116
148
1515
6
49
158
1582
0
5
164
1626
—
0
9
164
1622
8
53
155
1565
33
170
122
1369
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
1.3e-01
6.3e-01
—
—
—
6.3e-01
7.6e-01
cases:6.10%
controls:5.40%
cases:6.71%
controls:3.68%
—
—
—
—
—
—
cases:8.59%
controls:4.76%
cases:22.58%
controls:11.96%
10
88
154
1543
11
60
153
1571
—
—
—
14
77
149
1541
35
184
120
1355
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
3.6e-01
7.2e-01
—
—
—
6.3e-01
6.4e-01
cases:20.73%
controls:15.45%
cases:12.80%
controls:6.68%
—
—
—
—
—
—
cases:14.72%
controls:8.41%
cases:38.06%
controls:24.50%
34
252
130
1379
21
109
143
1522
—
—
—
24
136
139
1482
59
377
96
1162
Exploration of knee joint, arthroscopic
NGA30 [2001308091]
NGA30 [2001308091]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
164
1623
—
—
—
—
—
—
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
—
-1.0e+50
—
—
—
—
3.3e-01
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.23%
controls:2.34%
—
0
7
164
1624
—
—
—
—
5
36
150
1503
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
2.0e-01
7.3e-01
—
—
—
3.7e-01
-5.0e-02
cases:10.37%
controls:8.65%
cases:11.59%
controls:5.95%
—
—
—
—
—
—
cases:9.20%
controls:6.55%
cases:16.77%
controls:17.48%
17
141
147
1490
19
97
145
1534
—
—
—
15
106
148
1512
26
269
129
1270
Total laparoscopic hysterectomy
LCD01 [2001306585]
LCD01 [2001306585]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
SAA02 [2001310275]
1.3e-01
1.9e-01
—
—
-1.0e+50
4.0e-01
6.5e-01
cases:9.76%
controls:8.71%
cases:4.27%
controls:3.56%
—
—
—
—
cases:0.00%
controls:0.37%
cases:5.52%
controls:3.77%
cases:22.58%
controls:13.26%
16
142
148
1489
7
58
157
1573
—
—
0
6
164
1625
9
61
154
1557
35
204
120
1335
Pain localized to upper abdomen
R10.1 [45568111]
R10.1 [45568111]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
8
164
1623
—
—
—
—
—
chloramphenicol
S03AA08 [21605197]
S03AA08 [21605197]
—
—
—
—
—
—
7.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.97%
controls:5.59%
—
—
—
—
—
—
17
86
138
1453
Functional endoscopic opening of maxillary antrum
DMB20 [2001301780]
DMB20 [2001301780]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Left sided colitis
K51.5 [45533604]
K51.5 [45533604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
6.3e-01
4.6e-01
—
—
-1.0e+50
2.7e-01
5.7e-01
cases:7.32%
controls:4.05%
cases:3.66%
controls:2.33%
—
—
—
—
cases:0.00%
controls:0.49%
cases:3.07%
controls:2.35%
cases:9.03%
controls:5.33%
12
66
152
1565
6
38
158
1593
—
—
0
8
164
1623
5
38
158
1580
14
82
141
1457
Labour and delivery complicated by fetal heart rate anomaly
O68.0 [45548818]
O68.0 [45548818]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
10
155
1529
mometasone; nasal
R01AD09 [21605051]
R01AD09 [21605051]
1.3e-01
-2.6e-02
—
—
—
4.8e-01
-1.8e-01
cases:9.15%
controls:8.15%
cases:3.05%
controls:3.13%
—
—
—
—
—
—
cases:4.91%
controls:3.09%
cases:8.39%
controls:9.88%
15
133
149
1498
5
51
159
1580
—
—
—
8
50
155
1568
13
152
142
1387
Rheumatism, unspecified
M79.0 [45567658]
M79.0 [45567658]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
0
7
164
1624
0
5
164
1626
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
1.0e+00
-1.0e+50
—
—
—
—
7.4e-01
cases:4.27%
controls:1.59%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.56%
7
26
157
1605
0
9
164
1622
—
—
—
—
5
24
150
1515
Trochanteric bursitis
M70.6 [45606304]
M70.6 [45606304]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.04%
—
—
—
—
—
—
5
16
150
1523
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
39480-9 [3038515]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Release of median nerve
ACC51 [2001300642]
ACC51 [2001300642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
164
1624
—
—
—
—
—
—
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
9340-1 [3011831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
COVID-19, virus not identified
U07.2 [45756094]
U07.2 [45756094]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
12
164
1619
—
—
—
0
11
163
1607
—
Ulcerative colitis
K51 [45557655]
K51 [45557655]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Contusion of finger(s) without damage to nail
S60.0 [45535417]
S60.0 [45535417]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
ketoprofen; ointment
M02AA10 [21604046]
M02AA10 [21604046]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
11
164
1620
—
—
—
—
—
Coronary angiography
AN1 [2000200163]
AN1 [2000200163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
164
1624
—
—
—
—
—
—
Acromioplastia, arthroscopic
NBG15 [2001307302]
NBG15 [2001307302]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
6
163
1612
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
C03EA01 [21601543]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
Counselling related to known health issue
SPAT1310 [2001700411]
SPAT1310 [2001700411]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.74%
controls:3.38%
—
—
—
—
—
—
12
52
143
1487
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.10%
—
—
—
—
—
—
5
17
150
1522
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
2.7e-02
1.0e-01
—
—
—
—
1.3e-01
cases:6.10%
controls:5.95%
cases:3.05%
controls:2.76%
—
—
—
—
—
—
—
—
cases:6.45%
controls:5.72%
10
97
154
1534
5
45
159
1586
—
—
—
—
10
88
145
1451
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
Z20.8 [45542410]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
164
1622
—
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.10%
—
—
—
—
—
—
6
17
149
1522
Foreign body in cornea
T15.0 [45570142]
T15.0 [45570142]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
dequalinium; vaginal
G01AC05 [21602381]
G01AC05 [21602381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
F10.1 [45595844]
2.1e+00
—
—
—
—
—
1.6e+00
cases:3.05%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.65%
5
6
159
1625
—
—
—
—
—
5
10
150
1529
levonorgestrel
G03AC03 [21602499]
G03AC03 [21602499]
2.3e-01
—
—
—
—
-1.0e+50
1.5e-01
cases:4.27%
controls:3.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:4.52%
controls:3.90%
7
56
157
1575
—
—
—
—
0
10
163
1608
7
60
148
1479
Wrist X-ray examination
ND1AA [2001307576]
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
164
1626
—
—
—
—
—
0
6
155
1533
Organisation of medication
SPAT1251 [2001700352]
SPAT1251 [2001700352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
IDY03 [2001304164]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
—
—
—
—
—
—
9.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:2.86%
—
—
—
—
—
—
11
44
144
1495
Nonallergic asthma
J45.1 [45557625]
J45.1 [45557625]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
155
1530
Vacuum aspiration from uterus after delivery or abortion
MBA00 [2001306929]
MBA00 [2001306929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Audiometric test
21727005 [4071702]
21727005 [4071702]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
155
1530
Spondylolisthesis
M43.1 [45606219]
M43.1 [45606219]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
phenoxymethylpenicillin; oral
J01CE02 [21602842]
J01CE02 [21602842]
-1.3e-01
2.7e-01
-1.0e+50
—
—
—
-1.4e-01
cases:9.76%
controls:10.97%
cases:3.66%
controls:2.82%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:11.61%
controls:13.13%
16
179
148
1452
6
46
158
1585
0
5
164
1626
—
—
—
18
202
137
1337
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
—
—
—
—
—
-1.0e+50
1.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
cases:3.23%
controls:2.79%
—
—
—
—
—
0
14
163
1604
5
43
150
1496
Hand Surgery
40 [38004480]
40 [38004480]
5.2e-01
1.6e+00
—
—
—
—
—
cases:3.05%
controls:1.84%
cases:3.05%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
5
30
159
1601
5
10
159
1621
—
—
—
—
—
insulin (human); parenteral
A10AD01 [21600729]
A10AD01 [21600729]
5.5e-01
5.9e-01
—
—
-1.0e+50
—
—
cases:4.88%
controls:2.88%
cases:3.05%
controls:1.72%
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
8
47
156
1584
5
28
159
1603
—
—
0
8
164
1623
—
—
Cough
R05 [2002000886]
R05 [2002000886]
1.1e+00
—
—
—
—
—
—
cases:3.66%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
158
1610
—
—
—
—
—
—
melatonin; oral
N05CH01 [21604659]
N05CH01 [21604659]
—
-1.0e+50
—
—
—
-1.0e+50
6.6e-01
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:3.23%
controls:1.69%
—
0
8
164
1623
—
—
—
0
11
163
1607
5
26
150
1513
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
11572-5 [3021614]
7.4e-01
—
—
—
—
-1.0e+50
—
cases:3.05%
controls:1.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
5
24
159
1607
—
—
—
—
0
8
163
1610
—
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
-1.0e+50
—
—
—
—
—
1.7e+00
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.58%
0
6
164
1625
—
—
—
—
—
5
9
150
1530
Proliferative diabetic retinopathy
H36.03 [2000502323]
H36.03 [2000502323]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
6
164
1625
—
—
—
—
—
0
5
155
1534
oxcarbazepine; oral
N03AF02 [21604418]
N03AF02 [21604418]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
6
164
1625
—
—
—
—
0
5
163
1613
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
164
1620
—
—
—
—
—
—
Chronic hypertension
205 [2001600203]
205 [2001600203]
6.6e-01
—
—
—
—
—
—
cases:3.05%
controls:1.59%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
159
1605
—
—
—
—
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
8.6e-01
8.1e-01
—
—
-1.0e+50
6.6e-01
8.1e-01
cases:6.71%
controls:2.94%
cases:3.66%
controls:1.66%
—
—
—
—
cases:0.00%
controls:0.31%
cases:3.07%
controls:1.61%
cases:8.39%
controls:3.90%
11
48
153
1583
6
27
158
1604
—
—
0
5
164
1626
5
26
158
1592
13
60
142
1479
metoprolol; oral, parenteral
C07AB02 [21601684]
C07AB02 [21601684]
1.7e-01
—
-1.0e+50
—
—
—
3.4e-01
cases:3.05%
controls:2.58%
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:3.87%
controls:2.79%
5
42
159
1589
—
0
8
164
1623
—
—
—
6
43
149
1496
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
2.5e-01
3.1e-01
—
—
—
9.7e-01
2.2e-01
cases:10.98%
controls:8.77%
cases:3.66%
controls:2.70%
—
—
—
—
—
—
cases:6.75%
controls:2.66%
cases:10.32%
controls:8.45%
18
143
146
1488
6
44
158
1587
—
—
—
11
43
152
1575
16
130
139
1409
fluoxetine; oral
N06AB03 [21604711]
N06AB03 [21604711]
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.07%
controls:1.05%
—
—
—
—
—
—
—
5
17
158
1601
—
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
3.2e-01
8.3e-01
—
—
—
1.0e+00
6.5e-01
cases:5.49%
controls:4.05%
cases:4.27%
controls:1.90%
—
—
—
—
—
—
cases:4.91%
controls:1.79%
cases:11.61%
controls:6.43%
9
66
155
1565
7
31
157
1600
—
—
—
8
29
155
1589
18
99
137
1440
Pregnancy
W78 [2002001269]
W78 [2002001269]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
Tinea pedis
B35.3 [45581158]
B35.3 [45581158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
Lipid panel - Serum or Plasma
100898-6 [1761868]
100898-6 [1761868]
5.5e-01
—
—
—
—
—
2.3e-01
cases:4.27%
controls:2.51%
—
—
—
—
—
—
—
—
—
—
cases:7.74%
controls:6.24%
7
41
157
1590
—
—
—
—
—
12
96
143
1443
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:3.05%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
5
7
159
1624
—
—
—
—
—
0
7
155
1532
Cervicocranial syndrome
M53.0 [45562750]
M53.0 [45562750]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
0
11
164
1620
—
—
—
—
0
9
163
1609
—
Insulin glargine 300 U / ml
177 [2001600176]
177 [2001600176]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
K21.0 [45543296]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
8
164
1623
—
—
—
—
0
7
163
1611
—
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
14
155
1525
Cardiovascular stress test using bicycle ergometer
26046004 [4094501]
26046004 [4094501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
beclometasone; nasal
R01AD01 [21605043]
R01AD01 [21605043]
—
—
—
—
—
-1.0e+50
6.6e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:3.23%
controls:1.69%
—
—
—
—
—
0
8
163
1610
5
26
150
1513
celecoxib; oral
M01AH01 [21603992]
M01AH01 [21603992]
—
-1.0e+50
—
—
—
—
4.1e-01
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:3.87%
controls:2.60%
—
0
11
164
1620
—
—
—
—
6
40
149
1499
Testosterone Free [Moles/volume] in Serum or Plasma by calculation
96559-0 [36032269]
96559-0 [36032269]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
indometacin
C01EB03 [21600365]
C01EB03 [21600365]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:2.73%
—
—
—
—
—
—
8
42
147
1497
Periodontitis NOS
K05.32 [2000502730]
K05.32 [2000502730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
19113-0 [3005322]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
155
1527
Acute bronchitis
J20 [45581849]
J20 [45581849]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
Supervision of high-risk pregnancy, unspecified
Z35.9 [45576148]
Z35.9 [45576148]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Presbyopia
H52.4 [45605710]
H52.4 [45605710]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Respiratory infection other
R83 [2002000951]
R83 [2002000951]
7.8e-01
—
—
—
—
—
-1.0e+50
cases:3.66%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.08%
6
28
158
1603
—
—
—
—
—
0
32
155
1507
Low back pain
M54.5 [45553207]
M54.5 [45553207]
7.2e-01
—
—
—
—
—
6.7e-01
cases:5.49%
controls:2.76%
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:3.77%
9
45
155
1586
—
—
—
—
—
11
58
144
1481
buprenorphine; implant, parenteral, sublingual
N07BC01 [21604826]
N07BC01 [21604826]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
4.8e-01
7.4e-01
—
—
—
7.7e-01
8.5e-01
cases:6.10%
controls:3.86%
cases:3.66%
controls:1.78%
—
—
—
—
—
—
cases:4.29%
controls:2.04%
cases:11.61%
controls:5.33%
10
63
154
1568
6
29
158
1602
—
—
—
7
33
156
1585
18
82
137
1457
Periodontal treatment, brief
SDA02 [2001310327]
SDA02 [2001310327]
3.0e-01
—
—
—
—
—
-4.8e-02
cases:3.05%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:3.38%
5
37
159
1594
—
—
—
—
—
5
52
150
1487
sertraline; oral
N06AB06 [21604714]
N06AB06 [21604714]
—
—
—
—
—
—
8.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.69%
—
—
—
—
—
—
6
26
149
1513
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
DM1QA [2001301761]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Unspecified acute lower respiratory infection
J22 [45586665]
J22 [45586665]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
medroxyprogesterone; oral, parenteral
L02AB02 [21603821]
L02AB02 [21603821]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
8
164
1623
—
—
—
0
12
163
1606
—
Gynaecological examination (general)(routine)
Z01.4 [45542395]
Z01.4 [45542395]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
0
12
164
1619
—
—
—
0
7
163
1611
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.7e-01
—
—
—
—
—
8.4e-01
cases:3.05%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
cases:9.03%
controls:4.09%
5
42
159
1589
—
—
—
—
—
14
63
141
1476
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
53027-9 [3041942]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
6
163
1612
—
Observation for suspected nervous system disorder
Z03.3 [45609903]
Z03.3 [45609903]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
9
164
1622
—
—
—
—
—
0
11
155
1528
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
1.1e+00
—
—
—
—
—
—
cases:3.05%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
159
1614
—
—
—
—
—
—
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
2.7e-01
6.7e-01
—
—
—
3.9e-01
1.6e-01
cases:13.41%
controls:10.55%
cases:15.24%
controls:8.40%
—
—
—
—
—
—
cases:13.50%
controls:9.52%
cases:25.81%
controls:22.81%
22
172
142
1459
25
137
139
1494
—
—
—
22
154
141
1464
40
351
115
1188
ranitidine; oral, parenteral
A02BA02 [21600083]
A02BA02 [21600083]
1.0e+00
—
—
—
-1.0e+50
—
7.8e-01
cases:4.27%
controls:1.59%
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
cases:3.87%
controls:1.82%
7
26
157
1605
—
—
—
0
5
164
1626
—
6
28
149
1511
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
SDE04 [2001310352]
-1.0e+50
—
—
—
—
-1.0e+50
1.7e+00
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:3.87%
controls:0.71%
0
8
164
1623
—
—
—
—
0
5
163
1613
6
11
149
1528
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
1.7e-01
9.8e-01
—
—
—
—
2.3e-01
cases:3.05%
controls:2.58%
cases:3.05%
controls:1.16%
—
—
—
—
—
—
—
—
cases:5.81%
controls:4.68%
5
42
159
1589
5
19
159
1612
—
—
—
—
9
72
146
1467
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.91%
—
—
—
—
—
—
5
14
150
1525
Monitoring of normal pregnancy
SPAT1196 [2001700297]
SPAT1196 [2001700297]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.32%
0
10
164
1621
0
5
164
1626
—
—
—
0
7
163
1611
0
5
155
1534
Alveolitis of jaws
K10.3 [45591576]
K10.3 [45591576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Plugged feeling ear
H13 [2002000480]
H13 [2002000480]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
16
155
1523
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
—
—
-1.0e+50
—
—
—
1.1e+00
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:7.74%
controls:2.79%
—
—
0
6
164
1625
—
—
—
12
43
143
1496
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
2.1e-01
5.3e-01
—
—
-1.0e+50
2.1e-01
2.6e-01
cases:9.76%
controls:8.09%
cases:4.88%
controls:2.94%
—
—
—
—
cases:0.00%
controls:0.49%
cases:4.29%
controls:3.52%
cases:11.61%
controls:9.16%
16
132
148
1499
8
48
156
1583
—
—
0
8
164
1623
7
57
156
1561
18
141
137
1398
lymecycline; oral, parenteral
J01AA04 [21602802]
J01AA04 [21602802]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
7
163
1611
—
econazole; vaginal
G01AF05 [21602395]
G01AF05 [21602395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
164
1619
—
—
—
—
—
—
Heartburn
R12 [45539318]
R12 [45539318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
155
1530
vortioxetine; oral
N06AX26 [44819158]
N06AX26 [44819158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
155
1531
fluticasone furoate; nasal
R01AD12 [21605053]
R01AD12 [21605053]
3.0e-01
7.8e-01
—
—
—
1.8e-01
1.7e-01
cases:7.93%
controls:6.01%
cases:6.10%
controls:2.88%
—
—
—
—
—
—
cases:3.68%
controls:3.09%
cases:9.03%
controls:7.73%
13
98
151
1533
10
47
154
1584
—
—
—
6
50
157
1568
14
119
141
1420
Mouth breathing
R06.5 [45573006]
R06.5 [45573006]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
163
1613
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
1.4e+00
—
—
—
—
—
—
cases:3.05%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
159
1619
—
—
—
—
—
—
Localized swelling, mass and lump, upper limb
R22.3 [45548956]
R22.3 [45548956]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Place of Employment-Worksite
18 [581475]
18 [581475]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
164
1626
—
—
—
—
—
0
6
155
1533
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
10334-1 [3037551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
164
1621
—
—
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
47210-0 [3048773]
3.4e-01
1.5e-01
—
—
-1.0e+50
-1.3e-01
4.6e-01
cases:9.15%
controls:6.68%
cases:4.88%
controls:4.23%
—
—
—
—
cases:0.00%
controls:0.49%
cases:4.29%
controls:4.88%
cases:22.58%
controls:15.53%
15
109
149
1522
8
69
156
1562
—
—
0
8
164
1623
7
79
156
1539
35
239
120
1300
tranexamic acid; oral, parenteral
B02AA02 [21601036]
B02AA02 [21601036]
2.2e-01
—
—
—
—
—
—
cases:3.05%
controls:2.45%
—
—
—
—
—
—
—
—
—
—
—
—
5
40
159
1591
—
—
—
—
—
—
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
4.8e-01
—
-1.0e+50
—
—
—
2.9e-01
cases:9.15%
controls:5.89%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:7.10%
controls:5.39%
15
96
149
1535
—
0
5
164
1626
—
—
—
11
83
144
1456
Predominantly allergic asthma
J45.0 [45557624]
J45.0 [45557624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
0
17
155
1522
Unspecified fall
W19 [45756257]
W19 [45756257]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
14
155
1525
Diabetes, non-insulin-treated
215 [2001600211]
215 [2001600211]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.56%
—
—
—
—
—
—
6
24
149
1515
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
9.8e-01
—
—
—
—
—
1.0e+00
cases:3.66%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:1.88%
6
23
158
1608
—
—
—
—
—
8
29
147
1510
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
14685-2 [3009035]
—
-1.0e+50
—
—
—
—
8.9e-01
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.62%
—
0
8
164
1623
—
—
—
—
6
25
149
1514
Conjunctivitis, unspecified
H10.9 [45591253]
H10.9 [45591253]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
acetazolamide; oral, parenteral
S01EC01 [21603693]
S01EC01 [21603693]
—
1.0e+50
—
—
—
1.0e+50
—
—
—
cases:3.66%
controls:0.00%
—
—
—
—
—
—
cases:3.68%
controls:0.00%
—
—
—
6
0
158
1631
—
—
—
6
0
157
1618
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
1.0e+00
—
—
—
-1.0e+50
—
7.8e-01
cases:4.27%
controls:1.59%
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
cases:3.87%
controls:1.82%
7
26
157
1605
—
—
—
0
5
164
1626
—
6
28
149
1511
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
9.7e-01
—
—
—
—
—
—
cases:4.27%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
—
—
7
27
157
1604
—
—
—
—
—
—
Conisation of cervix uteri using diathermy or laser
LDC03 [2001306664]
LDC03 [2001306664]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Root filling of tooth with one root canal
SGB10 [2001310388]
SGB10 [2001310388]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
164
1618
—
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
—
-1.0e+50
—
—
—
—
6.6e-01
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.69%
—
0
9
164
1622
—
—
—
—
5
26
150
1513
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
J07BC02 [21601339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
155
1527
Extensive health check-up of expecting family
SPAT1197 [2001700298]
SPAT1197 [2001700298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
11
155
1528
Chronic gingivitis
K05.1 [45605912]
K05.1 [45605912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
155
1527
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
D01AE20 [21601959]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
0
7
164
1624
—
—
—
0
14
163
1604
—
escitalopram; oral
N06AB10 [21604718]
N06AB10 [21604718]
3.1e-01
8.9e-01
—
—
-1.0e+50
1.2e+00
6.0e-01
cases:3.66%
controls:2.70%
cases:3.66%
controls:1.53%
—
—
—
—
cases:0.00%
controls:0.61%
cases:4.29%
controls:1.36%
cases:6.45%
controls:3.64%
6
44
158
1587
6
25
158
1606
—
—
0
10
164
1621
7
22
156
1596
10
56
145
1483
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
2.1e-01
—
—
—
—
3.6e-01
3.8e-01
cases:4.27%
controls:3.49%
—
—
—
—
—
—
—
—
cases:3.07%
controls:2.16%
cases:8.39%
controls:5.91%
7
57
157
1574
—
—
—
—
5
35
158
1583
13
91
142
1448
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
6.5e-01
—
—
—
—
1.2e+00
1.8e-01
cases:6.71%
controls:3.62%
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.99%
cases:5.81%
controls:4.87%
11
59
153
1572
—
—
—
—
5
16
158
1602
9
75
146
1464
Pregnancy confirmed
Z32.1 [45566418]
Z32.1 [45566418]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
0
5
164
1626
—
—
—
—
0
7
155
1532
Lateral epicondylitis
M77.1 [45572551]
M77.1 [45572551]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
7
164
1624
—
—
—
—
0
7
163
1611
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
3.4e-01
—
—
—
—
8.1e-01
2.9e-01
cases:6.10%
controls:4.41%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.67%
cases:8.39%
controls:6.43%
10
72
154
1559
—
—
—
—
6
27
157
1591
13
99
142
1440
Screening procedure
SPAT1324 [2001700425]
SPAT1324 [2001700425]
—
—
—
—
—
—
-4.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:4.81%
—
—
—
—
—
—
5
74
150
1465
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
SAB02 [2001310280]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Dentistry
C5 [903277]
C5 [903277]
4.2e-01
—
—
—
—
—
7.9e-01
cases:3.05%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.49%
5
33
159
1598
—
—
—
—
—
5
23
150
1516
fusidic acid
D09AA02 [21602265]
D09AA02 [21602265]
3.9e-01
—
—
—
—
-1.0e+50
6.5e-01
cases:3.05%
controls:2.08%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:4.52%
controls:2.40%
5
34
159
1597
—
—
—
—
0
9
163
1609
7
37
148
1502
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
-2.6e-02
—
-1.0e+50
—
—
—
5.5e-01
cases:3.05%
controls:3.13%
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:6.45%
controls:3.83%
5
51
159
1580
—
0
7
164
1624
—
—
—
10
59
145
1480
Thoracic Surgery (Cardiothoracic Vascular Surgery) Physician
208G00000X [38004023]
208G00000X [38004023]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
Z30.1 [45537626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
35
164
1596
—
—
—
—
—
—
Obesity
E66 [45547648]
E66 [45547648]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
5
164
1626
0
6
164
1625
—
—
—
0
5
163
1613
—
Consultation of another employee
SPAT1260 [2001700361]
SPAT1260 [2001700361]
-1.0e+50
—
—
—
—
2.3e+00
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.31%
—
—
0
12
164
1619
—
—
—
—
5
5
158
1613
—
Cervicobrachial syndrome
M53.1 [45567577]
M53.1 [45567577]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.36%
—
—
—
—
—
—
5
21
150
1518
Pregnancy high risk
W84 [2002001275]
W84 [2002001275]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
6
164
1625
—
—
—
—
0
6
163
1612
—
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
3.8e-01
—
-1.0e+50
—
—
—
1.9e-01
cases:7.93%
controls:5.58%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:6.45%
controls:5.39%
13
91
151
1540
—
0
5
164
1626
—
—
—
10
83
145
1456
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
1.9e-01
5.0e-01
—
—
—
-2.6e-01
3.8e-01
cases:22.56%
controls:19.44%
cases:9.76%
controls:6.13%
—
—
—
—
—
—
cases:5.52%
controls:7.05%
cases:28.39%
controls:21.31%
37
317
127
1314
16
100
148
1531
—
—
—
9
114
154
1504
44
328
111
1211
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
10
164
1621
—
—
—
—
0
7
163
1611
—
Excision of plica of synovy of knee
NGF00 [2001308129]
NGF00 [2001308129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
Contusion of knee
S80.0 [45569633]
S80.0 [45569633]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Seborrhoeic keratosis
L82 [45548208]
L82 [45548208]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
13
155
1526
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
164
1615
—
—
—
—
—
—
Shoulder lesions
M75 [45557983]
M75 [45557983]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
155
1533
HLA-B27 [Presence]
4821-5 [3008898]
4821-5 [3008898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
164
1624
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
31017-7 [3019050]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.52%
controls:2.27%
—
—
—
—
—
—
7
35
148
1504
ketorolac
S01BC05 [21603643]
S01BC05 [21603643]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.32%
—
—
—
—
—
—
5
5
150
1534
adalimumab; parenteral
L04AB04 [21603911]
L04AB04 [21603911]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
Supervision of normal first pregnancy
Z34.0 [45595500]
Z34.0 [45595500]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
10
164
1621
—
—
—
—
—
0
7
155
1532
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
4.9e-01
1.2e+00
—
—
—
9.7e-01
9.3e-01
cases:5.49%
controls:3.43%
cases:3.05%
controls:0.92%
—
—
—
—
—
—
cases:3.68%
controls:1.42%
cases:10.32%
controls:4.35%
9
56
155
1575
5
15
159
1616
—
—
—
6
23
157
1595
16
67
139
1472
Injury of extensor muscle and tendon of other finger at wrist and hand level
S66.3 [45603257]
S66.3 [45603257]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Acute conjunctivitis, unspecified
H10.3 [45566958]
H10.3 [45566958]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
8.3e-01
—
-1.0e+50
—
—
7.4e-01
3.9e-01
cases:11.59%
controls:5.40%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
cases:3.68%
controls:1.79%
cases:11.61%
controls:8.19%
19
88
145
1543
—
0
5
164
1626
—
—
6
29
157
1589
18
126
137
1413
Outcome of delivery
Z37 [45581024]
Z37 [45581024]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
cases:0.00%
controls:1.24%
—
—
—
0
14
164
1617
—
—
—
0
20
163
1598
—
Epilepsy and comparable convulsive disorders
111 [2001600111]
111 [2001600111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
trimethoprim; oral, parenteral
J01EA01 [21602931]
J01EA01 [21602931]
2.0e-01
—
—
—
—
—
7.2e-01
cases:3.66%
controls:3.00%
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:2.92%
6
49
158
1582
—
—
—
—
—
9
45
146
1494
frovatriptan; oral
N02CC07 [21604382]
N02CC07 [21604382]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.78%
—
—
—
—
—
0
9
163
1609
0
12
155
1527
Microsurgical excision of lumbar intervertebral disc displacement
ABC16 [2001300466]
ABC16 [2001300466]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
164
1623
—
—
—
—
—
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
11054-4 [3002109]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
8
164
1623
—
—
—
—
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
K08.1 [45591573]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
Emergency Medicine
93 [38004510]
93 [38004510]
-1.9e-01
—
-1.0e+50
—
—
—
2.1e-01
cases:3.05%
controls:3.68%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:8.39%
controls:6.89%
5
60
159
1571
—
0
5
164
1626
—
—
—
13
106
142
1433
Toothache NOS
K08.80 [2000502799]
K08.80 [2000502799]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.58%
—
—
—
—
—
0
5
163
1613
0
9
155
1530
cisapride; oral, rectal
A03FA02 [21600485]
A03FA02 [21600485]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
164
1619
—
—
—
—
—
—
Incomplete uterovaginal prolapse
N81.2 [45596883]
N81.2 [45596883]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Other blockage of nerve
WX290 [2001310792]
WX290 [2001310792]
4.1e-01
6.7e-01
-1.0e+50
—
-1.0e+50
3.9e-01
6.4e-01
cases:7.93%
controls:5.40%
cases:3.66%
controls:1.90%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.43%
cases:3.07%
controls:2.10%
cases:14.84%
controls:8.38%
13
88
151
1543
6
31
158
1600
0
5
164
1626
—
0
7
164
1624
5
34
158
1584
23
129
132
1410
Demanding periodontal treatment
SDA04 [2001310329]
SDA04 [2001310329]
-1.0e+50
—
—
—
—
—
1.6e-01
cases:0.00%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:3.31%
0
30
164
1601
—
—
—
—
—
6
51
149
1488
Allergic rhinitis due to pollen
J30.10 [2000502594]
J30.10 [2000502594]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
7
164
1624
—
—
—
—
—
0
7
155
1532
Amniocentesis
MAA00 [2001306845]
MAA00 [2001306845]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
A48 [2002000182]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
SPAT1306 [2001700407]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
0
5
164
1626
—
—
—
—
—
hydrochlorothiazide; oral
C03AA03 [21601466]
C03AA03 [21601466]
—
—
—
—
—
—
6.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.75%
—
—
—
—
—
—
5
27
150
1512
Personal history of diseases of the digestive system
Z87.1 [45542474]
Z87.1 [45542474]
8.5e-01
—
—
—
—
—
6.6e-01
cases:6.10%
controls:2.70%
—
—
—
—
—
—
—
—
—
—
cases:11.61%
controls:6.37%
10
44
154
1587
—
—
—
—
—
18
98
137
1441
Pulpit UNS
K04.09 [2000502704]
K04.09 [2000502704]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
155
1530
Wrist symptom/complaint
L11 [2002000635]
L11 [2002000635]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
0
18
164
1613
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
0
9
164
1622
0
7
164
1624
0
6
164
1625
—
—
—
—
glycerol; rectal
A06AG04 [21600587]
A06AG04 [21600587]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
insulin (human); parenteral
A10AB01 [21600715]
A10AB01 [21600715]
6.8e-01
—
—
—
-1.0e+50
—
—
cases:4.27%
controls:2.21%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
7
36
157
1595
—
—
—
0
8
164
1623
—
—
Laparoscopic sterilisation by constriction of Fallopian tubes
LGA21 [2001306793]
LGA21 [2001306793]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
10
164
1621
—
—
—
—
—
0
6
155
1533
Vacuum extractor delivery
O81.4 [45582577]
O81.4 [45582577]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
164
1626
—
—
—
—
—
0
6
155
1533
Headache
N01 [2002000720]
N01 [2002000720]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
Z03.5 [45590692]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
164
1624
—
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
—
—
—
—
—
—
4.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:2.47%
—
—
—
—
—
—
6
38
149
1501
lovastatin; oral
C10AA02 [21601857]
C10AA02 [21601857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
General medical examination
Z00.0 [45585791]
Z00.0 [45585791]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.36%
—
—
—
—
—
—
6
21
149
1518
Pulmonary Disease
29 [38004472]
29 [38004472]
3.3e-01
8.3e-01
-1.0e+50
—
—
7.6e-01
4.0e-01
cases:6.71%
controls:4.90%
cases:4.27%
controls:1.90%
cases:0.00%
controls:0.31%
—
—
—
—
cases:4.91%
controls:2.35%
cases:8.39%
controls:5.78%
11
80
153
1551
7
31
157
1600
0
5
164
1626
—
—
8
38
155
1580
13
89
142
1450
clindamycin
D10AF01 [21602305]
D10AF01 [21602305]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.58%
—
—
—
—
—
0
6
163
1612
0
9
155
1530
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
—
—
—
—
—
—
4.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:2.53%
—
—
—
—
—
—
6
39
149
1500
olanzapine; oral, parenteral
N05AH03 [21604543]
N05AH03 [21604543]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.10%
—
—
—
—
—
—
6
17
149
1522
Psoriasis vulgaris
L40.0 [45543370]
L40.0 [45543370]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
9
164
1622
0
5
164
1626
—
—
—
0
7
163
1611
—
norethisterone and ethinylestradiol
G03AA05 [21602478]
G03AA05 [21602478]
—
—
—
—
—
—
9.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.52%
controls:1.75%
—
—
—
—
—
—
7
27
148
1512
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.71%
—
—
—
—
—
—
5
11
150
1528
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
1.1e+00
—
—
—
—
—
—
cases:3.05%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
159
1614
—
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-2.3e-02
8.5e-01
—
—
—
4.2e-01
4.8e-01
cases:7.93%
controls:8.09%
cases:12.20%
controls:5.58%
—
—
—
—
—
—
cases:8.59%
controls:5.81%
cases:21.94%
controls:14.75%
13
132
151
1499
20
91
144
1540
—
—
—
14
94
149
1524
34
227
121
1312
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.71%
—
—
—
—
—
—
6
11
149
1528
chloramphenicol
S01AA01 [21603554]
S01AA01 [21603554]
—
—
—
—
—
—
7.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.97%
controls:5.59%
—
—
—
—
—
—
17
86
138
1453
Sleep apnoea
G47.3 [45562094]
G47.3 [45562094]
2.8e-01
7.0e-01
-1.0e+50
—
—
—
8.3e-01
cases:3.05%
controls:2.33%
cases:3.05%
controls:1.53%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:6.45%
controls:2.92%
5
38
159
1593
5
25
159
1606
0
6
164
1625
—
—
—
10
45
145
1494
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
5.7e-01
8.7e-01
—
—
—
6.4e-01
1.7e-01
cases:4.88%
controls:2.82%
cases:4.27%
controls:1.84%
—
—
—
—
—
—
cases:3.68%
controls:1.98%
cases:5.81%
controls:4.94%
8
46
156
1585
7
30
157
1601
—
—
—
6
32
157
1586
9
76
146
1463
Simple extraction of IUD
TLC02 [2001306648]
TLC02 [2001306648]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
7
164
1624
—
—
—
—
—
0
5
155
1534
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
2.7e-01
6.7e-01
—
—
—
3.9e-01
1.6e-01
cases:13.41%
controls:10.55%
cases:15.24%
controls:8.40%
—
—
—
—
—
—
cases:13.50%
controls:9.52%
cases:25.81%
controls:22.87%
22
172
142
1459
25
137
139
1494
—
—
—
22
154
141
1464
40
352
115
1187
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
2.3e-01
—
—
—
—
-7.5e-02
-1.8e-01
cases:15.85%
controls:13.00%
—
—
—
—
—
—
—
—
cases:3.68%
controls:3.96%
cases:9.68%
controls:11.37%
26
212
138
1419
—
—
—
—
6
64
157
1554
15
175
140
1364
Curettage of cervix uteri
LDA10 [2001306655]
LDA10 [2001306655]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
Gonarthrosis, unspecified
M17.9 [45606128]
M17.9 [45606128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
Other specified dysphonia
R49.08 [2000503601]
R49.08 [2000503601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
SFA10 [2001310358]
2.9e-01
—
-1.0e+50
—
—
8.5e-01
2.5e-01
cases:6.71%
controls:5.09%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
cases:6.13%
controls:2.72%
cases:12.90%
controls:10.33%
11
83
153
1548
—
0
6
164
1625
—
—
10
44
153
1574
20
159
135
1380
Elbow symptom/complaint
L10 [2002000634]
L10 [2002000634]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
155
1530
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
4.7e-01
6.7e-01
—
—
-1.0e+50
—
2.8e-02
cases:7.32%
controls:4.72%
cases:3.66%
controls:1.90%
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:5.81%
controls:5.65%
12
77
152
1554
6
31
158
1600
—
—
0
6
164
1625
—
9
87
146
1452
tacrolimus
D11AH01 [21602338]
D11AH01 [21602338]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
164
1623
—
—
—
—
—
—
Corneal ulcer
H16.0 [45557339]
H16.0 [45557339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
164
1625
—
—
—
—
—
—
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
H35.31 [2000502315]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.00%
cases:3.87%
controls:0.00%
—
—
—
—
—
5
0
158
1618
6
0
149
1539
Vaccination
SPAT1325 [2001700426]
SPAT1325 [2001700426]
—
—
—
—
—
1.3e+00
8.5e-01
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.05%
cases:6.45%
controls:2.86%
—
—
—
—
—
6
17
157
1601
10
44
145
1495
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
—
—
—
—
—
—
9.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:2.01%
—
—
—
—
—
—
8
31
147
1508
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
SDE03 [2001310351]
—
—
—
—
—
—
8.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:3.31%
—
—
—
—
—
—
11
51
144
1488
Carpal tunnel syndrome
G56.0 [45566891]
G56.0 [45566891]
—
—
—
—
—
-1.0e+50
8.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:3.23%
controls:1.36%
—
—
—
—
—
0
5
163
1613
5
21
150
1518
Pain in joint
M25.5 [45586941]
M25.5 [45586941]
2.2e-01
—
—
—
—
—
9.2e-01
cases:3.05%
controls:2.45%
—
—
—
—
—
—
—
—
—
—
cases:7.74%
controls:3.25%
5
40
159
1591
—
—
—
—
—
12
50
143
1489
Contraception intrauterine
W12 [2002001212]
W12 [2002001212]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
14
164
1617
—
—
—
—
0
6
163
1612
—
baclofen; oral, parenteral
M03BX01 [21604115]
M03BX01 [21604115]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
155
1532
enalapril and diuretics
C09BA02 [21601804]
C09BA02 [21601804]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.31%
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
0
9
164
1622
0
5
164
1626
—
—
0
10
163
1608
—
Dermatitis due to ingested food
L27.2 [45596371]
L27.2 [45596371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
1.2e+00
—
—
—
—
—
—
cases:3.66%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
19
158
1612
—
—
—
—
—
—
Operative extraction of tooth
EBA10 [2001301925]
EBA10 [2001301925]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
155
1527
terbinafine; oral
D01BA02 [21601967]
D01BA02 [21601967]
—
—
—
—
—
—
8.3e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:3.57%
—
—
—
—
—
—
6
55
149
1484
Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose
14759-5 [3016701]
14759-5 [3016701]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
155
1534
metronidazole; vaginal
G01AF01 [21602392]
G01AF01 [21602392]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
13
164
1618
—
—
—
0
12
163
1606
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
SMOKING-1-1-1 [2002330115]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
0
13
164
1618
—
—
—
—
—
lisinopril and diuretics
C09BA03 [21601805]
C09BA03 [21601805]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.45%
—
—
—
—
—
0
5
163
1613
0
7
155
1532
Other health check-up
SPAT1370 [2001700471]
SPAT1370 [2001700471]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
164
1626
—
—
—
—
—
—
Pediatric Medicine
37 [38004477]
37 [38004477]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.93%
—
—
—
0
13
164
1618
—
—
0
5
164
1626
0
15
163
1603
—
telithromycin; oral
J01FA15 [21602983]
J01FA15 [21602983]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
8
163
1610
—
Handing over of treatment supplies
SPAT1262 [2001700363]
SPAT1262 [2001700363]
1.4e+00
—
—
—
—
1.5e+00
1.3e+00
cases:3.05%
controls:0.80%
—
—
—
—
—
—
—
—
cases:3.07%
controls:0.68%
cases:5.81%
controls:1.69%
5
13
159
1618
—
—
—
—
5
11
158
1607
9
26
146
1513
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
1.5e+00
—
—
—
—
—
—
cases:3.05%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
5
11
159
1620
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
89
584
2.15
5.43
6.6
6.1
1.22
1.21
mmol/l
0.71
82
549
88
580
2.12
5.25
5.6
5.2
35.64
36.70
g/l
1.10
80
560
53
296
2.17
4.78
2.8
2.0
2.53
2.86
mg/l
0.65
43
261
11
19
6.12
4.52
2.6
2.8
8.93
5.52
pmol/l
0.56
11
19
93
650
2.00
4.48
9.1
7.3
1.22
1.21
mmol/l
0.39
72
579
59
353
2.05
4.39
3.5
2.8
0.08
0.31
e6/l
2.28
46
244
68
431
1.99
4.30
5.8
3.8
7.65
5.78
mg/mmol
0.23
44
267
88
610
1.96
4.28
3.0
2.5
75.00
75.76
nmol/l
0.09
83
572
11
22
5.28
4.08
2.5
4.1
5.24
5.16
kpa
0.11
11
22
22
90
2.67
3.91
4.5
9.9
23.60
25.01
mmol/l
0.63
22
90
82
567
1.89
3.91
2.9
3.6
26.66
30.02
u/l
0.99
74
545
69
457
1.88
3.71
3.8
3.8
2.35
2.35
mmol/l
0.04
64
428
31
161
2.14
3.27
2.2
1.6
1366.42
1297.87
nmol/l
0.15
23
127
6
8
7.73
3.08
1.3
1.3
1.88
1.70
mmol/l
—
6
8
53
340
1.83
3.06
2.3
3.0
422.42
661.58
ng/l
0.94
40
283
12
37
3.42
3.00
2.2
1.5
—
—
—
0
0
58
393
1.74
2.74
4.7
3.4
0.00
0.00
estimate
-0.00
26
143
97
761
1.67
2.62
6.9
6.7
10.76
10.96
umol/l
0.08
92
737
12
45
2.80
2.51
1.2
1.4
365.00
302.73
ug/g
—
5
29
14
58
2.55
2.44
2.0
1.4
—
—
—
0
0
33
196
1.86
2.39
2.6
2.7
4.82
6.20
umol/l
0.71
28
177
5
8
6.40
2.39
4.8
5.4
484.20
622.50
u/ml
—
5
8
101
816
1.62
2.30
7.2
5.0
6.75
6.61
mmol/l
0.29
96
779
130
1131
1.72
2.10
6.1
4.4
14.85
14.58
pmol/l
0.66
121
1065
21
114
1.97
1.98
4.6
2.9
—
—
—
0
0
8
27
3.06
1.96
1.1
1.2
—
—
—
0
0
127
1108
1.65
1.92
10.4
8.2
75.28
78.22
u/l
0.42
121
1059
29
183
1.71
1.72
7.9
7.4
104.97
104.45
mmol/l
0.17
29
183
66
509
1.50
1.70
4.3
3.1
32.89
35.58
ng/l
0.07
48
307
16
84
2.00
1.66
11.2
10.3
15.91
16.40
%
0.29
16
78
9
38
2.45
1.48
2.1
2.0
25.21
24.88
mmol/l
—
9
38
7
28
2.56
1.47
1.3
1.3
—
—
—
0
0
47
347
1.50
1.47
1.8
1.6
22.58
21.28
nmol/l
0.20
41
310
91
764
1.43
1.44
5.1
3.4
0.00
0.00
estimate
-0.00
28
148
11
53
2.15
1.42
1.3
1.4
—
—
—
0
0
153
1434
2.00
1.42
4.9
4.3
1.42
1.32
mmol/l
0.78
143
1359
100
856
1.43
1.41
10.2
11.1
3.74
4.00
e9/l
0.84
92
740
23
146
1.67
1.35
8.8
9.7
13.08
13.14
kpa
0.02
23
137
23
146
1.67
1.35
8.8
9.7
4.75
5.16
kpa
1.27
23
135
36
256
1.52
1.33
4.9
3.8
18.15
813.04
ng/l
1.90
26
178
21
131
1.69
1.31
9.2
10.2
124.24
124.85
g/l
0.05
21
125
81
675
1.40
1.30
2.3
1.9
1.59
1.44
mmol/l
0.68
66
588
122
1093
1.45
1.27
5.9
4.2
12.11
9.28
mm/h
1.77
113
1041
6
25
2.45
1.25
2.2
1.6
—
—
—
0
0
43
322
1.45
1.24
5.2
3.5
1.02
1.02
kg/l
0.61
36
211
34
243
1.50
1.23
2.6
1.6
482.24
450.09
pmol/l
0.15
25
219
69
564
1.39
1.22
2.4
1.9
96.03
98.54
pmol/l
0.14
37
290
15
243
0.58
1.20
2.1
2.2
3.48
3.48
ratio
—
10
198
88
752
1.37
1.17
5.1
3.4
0.00
0.00
estimate
-0.00
27
146
33
239
1.48
1.12
3.3
2.8
2.43
2.43
mmol/l
0.04
27
217
48
376
1.39
1.08
1.5
1.4
0.45
1.70
u/ml
1.47
13
119
87
763
1.30
0.89
5.3
3.5
0.00
0.02
estimate
0.50
24
139
69
587
1.30
0.88
5.2
3.2
0.00
0.01
estimate
0.50
24
123
39
308
1.35
0.83
1.3
1.3
25.97
8.72
u/ml
0.43
15
123
41
331
1.32
0.75
1.7
1.7
0.92
1.06
mg/l
0.14
32
258
12
76
1.62
0.74
3.5
2.3
21.33
24.65
mmol/l
1.47
12
76
5
27
1.88
0.69
1.0
1.6
—
—
—
0
0
141
1340
1.37
0.68
7.5
5.2
1.96
1.87
mu/l
0.29
134
1266
12
176
0.66
0.66
1.4
2.0
—
—
—
0
0
30
374
0.76
0.66
3.6
3.9
17.92
20.97
%
0.44
11
140
17
121
1.45
0.65
1.6
1.3
65.39
151.87
u/ml
—
8
50
0
20
0.00
0.61
0.0
2.2
—
13.58
—
0
20
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
22
0.00
0.60
0.0
1.2
—
—
—
0
0
0
22
0.00
0.60
0.0
1.1
—
—
—
0
0
147
1413
1.39
0.58
6.1
4.5
6.12
5.85
mmol/l
1.42
135
1349
13
182
0.69
0.58
1.9
2.0
3.29
3.61
mmol/l
—
8
140
154
1493
1.52
0.56
6.2
5.1
4.78
4.82
mmol/l
0.18
147
1436
6
37
1.64
0.56
1.5
1.2
—
—
—
0
0
37
307
1.26
0.56
1.6
1.6
—
—
—
0
0
155
1507
1.52
0.54
6.8
5.5
2.86
2.87
mmol/l
0.06
147
1444
15
109
1.41
0.53
3.1
3.7
4.11
4.61
pmol/l
2.57
15
93
12
84
1.46
0.51
1.4
1.8
—
—
—
0
0
26
211
1.28
0.47
3.5
2.5
2.39
2.06
e6/l
0.08
15
96
45
390
1.21
0.46
2.3
2.4
320.90
336.15
umol/l
0.53
40
354
52
460
1.19
0.43
5.1
2.7
53.96
67.79
u/l
0.72
46
438
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
25
206
1.25
0.41
1.4
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
153
1492
1.38
0.41
6.2
5.0
1.44
1.47
mmol/l
0.34
146
1428
5
34
1.48
0.40
7.6
1.5
0.85
0.95
nmol/l
—
5
28
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
28
235
1.23
0.39
3.9
2.5
0.82
0.84
e6/l
0.03
17
120
50
447
1.17
0.37
5.3
2.7
0.00
0.02
estimate
0.80
23
115
15
118
1.30
0.35
1.9
2.1
47.43
74.13
ml/min/173m2
—
7
48
71
657
1.14
0.33
3.3
2.6
—
—
estimate
—
0
0
7
96
0.72
0.32
1.0
1.1
0.97
0.91
g/l
—
7
96
18
148
1.24
0.31
5.4
5.9
—
—
—
0
0
39
348
1.16
0.29
1.3
1.3
18.73
32.71
iu/ml
0.91
14
117
16
194
0.81
0.29
1.4
2.1
—
—
—
0
0
8
62
1.30
0.28
2.4
1.5
—
—
—
0
0
8
66
1.22
0.27
1.0
1.6
—
—
—
0
0
7
95
0.73
0.23
1.0
1.1
1.43
1.56
g/l
—
7
95
5
40
1.26
0.22
1.6
1.2
—
—
—
0
0
5
41
1.23
0.22
1.2
1.5
0.00
0.00
g/l
—
5
41
5
41
1.23
0.22
1.2
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
11.25
—
0
12
0
12
0.00
0.21
0.0
1.1
—
1.10
—
0
12
0
13
0.00
0.21
0.0
1.1
—
2.98
—
0
13
6
48
1.26
0.20
2.3
2.6
23.93
24.26
mmol/l
—
6
43
120
1167
1.11
0.19
3.4
3.4
44.13
46.50
u/l
0.20
112
1136
100
1034
0.92
0.18
3.0
3.4
—
—
—
0
0
145
1427
1.14
0.16
19.1
12.4
84.55
86.86
ml/min/173m2
0.75
137
1327
143
1450
0.89
0.13
21.2
13.5
21.66
21.00
mg/l
0.08
118
1150
5
46
1.09
0.09
1.4
1.2
—
—
—
0
0
6
58
1.04
0.08
1.3
1.4
—
—
—
0
0
27
256
1.07
0.06
1.1
1.5
—
—
—
0
0
45
466
0.95
0.06
5.5
4.2
1.43
1.63
ug/l
0.37
39
429
28
289
0.96
0.02
2.7
2.6
0.65
0.70
ug/l
0.19
19
151
16
152
1.06
0.02
1.3
1.9
—
—
—
0
0
17
163
1.05
0.01
1.2
1.9
—
—
—
0
0
12
126
0.95
0.00
1.6
1.5
—
—
—
0
0
34
335
1.02
0.00
2.9
2.1
—
—
—
0
0
5
52
0.96
0.00
1.2
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
79
0.88
-0.00
1.3
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
58
0.86
-0.00
1.2
1.5
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
8
0.00
-0.00
0.0
1.0
—
122.63
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
110.00
—
0
9
0
6
0.00
-0.00
0.0
2.0
—
63.43
—
0
6
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
9
0.00
-0.00
0.0
2.2
—
115.56
—
0
9
0
9
0.00
-0.00
0.0
1.1
—
1316.44
—
0
9
7
76
0.92
-0.00
2.4
2.3
4.93
2.93
mg/l
—
7
58
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
98.33
—
0
9
0
9
0.00
-0.00
0.0
4.6
—
18.48
—
0
9
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
15.10
—
0
6
7
77
0.91
-0.00
2.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
156.20
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: DRY_AMD_EARLY – Dry age-related macular degeneration (includes geographic atrophy), under 50 years
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).